Chad Thomas Campbell - Jul 19, 2023 Form 4/A - restatement Insider Report for ANGIODYNAMICS INC (ANGO)

Role
SVP/GM, Vascular Access
Signature
/s/ Stephen A. Trowbridge, Attorney in Fact
Stock symbol
ANGO
Transactions as of
Jul 19, 2023
Transactions value $
-$27,679
Form type
4/A - RESTATEMENT
Date filed
9/21/2023, 10:12 PM
Date Of Original Report
Jul 26, 2023
Previous filing
Jul 18, 2023
Next filing
Jul 25, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction ANGO Common Stock Options Exercise $0 +8.61 K +18.12% $0.00 56.1 K Jul 19, 2023 Direct F1
transaction ANGO Common Stock Tax liability -$27.7 K -3.1 K -5.53% $8.92 53 K Jul 19, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANGO Performance Right Options Exercise $0 -13.5 K -100% $0.00 0 Jul 19, 2023 Common Stock 13.5 K Direct F3

Explanation of Responses:

Id Content
F1 This acquisition of 8,610 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.
F2 The exempt disposition of 3,103 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.
F3 On July 14, 2020, the reporting person received a target grant of 13,453 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 8,610 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

Remarks:

This Form 4/A is being filed to correct the number of shares received by the Reporting Person and subsequently sold to satisfy tax withholding obligations in connection with the vesting and settlement of performance share units on 07/19/2023 and provides corrected amounts in Columns 4 and 5 of Table I.